Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity.
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …

Small-cell lung cancer (SCLC) represents about 15% of all lung cancers and is marked by
an exceptionally high proliferative rate, strong predilection for early metastasis and poor …

Introduction Recent studies have identified subtypes of small cell lung carcinoma (SCLC)
defined by the RNA expression of ASCL1, NEUROD1, POU2F3, and YAP1 transcriptional …

Small cell lung cancer (SCLC) is characterized by morphologic, epigenetic and
transcriptomic heterogeneity. Subtypes based upon predominant transcription factor …

Small cell lung cancer (SCLC) is a neuroendocrine tumor treated clinically as a single
disease with poor outcomes. Distinct SCLC molecular subtypes have been defined based …

Intratumour heterogeneity (ITH) is a hallmark of cancer that drives tumour evolution and
disease progression. Technological and computational advances have enabled us to …

Predictive biomarkers aid selection of personalized therapy targeted to molecular alterations
within an individual's tumor. Patients' responses to targeted therapies are commonly …

Small cell lung cancer (SCLC) exists broadly in four molecular subtypes: ASCL1,
NEUROD1, POU2F3 and Inflammatory. Initially, SCLC subtypes were thought to be mutually …

Metastasis is a major cause of morbidity and mortality in cancer patients. However, the
molecular and cellular mechanisms underlying the ability of cancer cells to metastasize …

Small cell lung cancer (SCLC) is notorious for its early and frequent metastases, which
contribute to it as a recalcitrant malignancy. To understand the molecular mechanisms …